Metabolic Disorders Therapeutics Market Research Report by Disease Type, Product, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

Metabolic Disorders Therapeutics Market Research Report by Disease Type, Product, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

The United States Metabolic Disorders Therapeutics Market size was estimated at USD 10.59 billion in 2021 and expected to reach USD 12.09 billion in 2022, and is projected to grow at a CAGR 10.56% to reach USD 19.35 billion by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Metabolic Disorders Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease Type, the market was studied across Diabetes, Hypercholesterolemia, Lysosomal Storage Disease, and Obesity.

Based on Product, the market was studied across Globoid Leukodystrophy, Hepatic Encephalopathy, and Metachromatic Leukodystrophy.

Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Metabolic Disorders Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Metabolic Disorders Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Metabolic Disorders Therapeutics Market, including Abbvie, Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astazeneca Plc, Biocon, Eli Lily, Merck, Novo Nordisk, and Sanofi.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Metabolic Disorders Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Metabolic Disorders Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Metabolic Disorders Therapeutics Market?
4. What is the competitive strategic window for opportunities in the United States Metabolic Disorders Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the United States Metabolic Disorders Therapeutics Market?
6. What is the market share of the leading vendors in the United States Metabolic Disorders Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the United States Metabolic Disorders Therapeutics Market?

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Metabolic Disorders Therapeutics Market, by Disease Type
6.1. Introduction
6.2. Diabetes
6.3. Hypercholesterolemia
6.4. Lysosomal Storage Disease
6.5. Obesity
7. Metabolic Disorders Therapeutics Market, by Product
7.1. Introduction
7.2. Globoid Leukodystrophy
7.3. Hepatic Encephalopathy
7.4. Metachromatic Leukodystrophy
8. California Metabolic Disorders Therapeutics Market
8.1. Introduction
9. Florida Metabolic Disorders Therapeutics Market
9.1. Introduction
10. Illinois Metabolic Disorders Therapeutics Market
10.1. Introduction
11. New York Metabolic Disorders Therapeutics Market
11.1. Introduction
12. Ohio Metabolic Disorders Therapeutics Market
12.1. Introduction
13. Pennsylvania Metabolic Disorders Therapeutics Market
13.1. Introduction
14. Texas Metabolic Disorders Therapeutics Market
14.1. Introduction
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbvie
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Actelion Pharmaceuticals
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. Amicus Therapeutics
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. Arena Pharmaceuticals
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. Astazeneca Plc
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. Biocon
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Eli Lily
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. Merck
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. Novo Nordisk
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. Sanofi
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 4. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 6. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 10. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY DISEASE TYPE, 2027
FIGURE 11. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, 2018-2027 (USD BILLION)
FIGURE 12. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, 2018-2027 (USD BILLION)
FIGURE 13. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, 2018-2027 (USD BILLION)
FIGURE 14. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, 2018-2027 (USD BILLION)
FIGURE 15. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 16. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD BILLION)
FIGURE 17. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2027
FIGURE 18. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, 2018-2027 (USD BILLION)
FIGURE 19. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, 2018-2027 (USD BILLION)
FIGURE 20. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, 2018-2027 (USD BILLION)
FIGURE 21. CALIFORNIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 22. FLORIDA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 23. ILLINOIS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 24. NEW YORK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 25. OHIO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 26. PENNSYLVANIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 27. TEXAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 28. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 29. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 30. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2021
TABLE 3. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 4. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2027 (USD BILLION)
TABLE 5. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 6. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, 2018-2027 (USD BILLION)
TABLE 7. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY STATE, 2018-2027 (USD BILLION)
TABLE 8. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, 2018-2027 (USD BILLION)
TABLE 9. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY STATE, 2018-2027 (USD BILLION)
TABLE 10. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, 2018-2027 (USD BILLION)
TABLE 11. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY STATE, 2018-2027 (USD BILLION)
TABLE 12. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, 2018-2027 (USD BILLION)
TABLE 13. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY STATE, 2018-2027 (USD BILLION)
TABLE 14. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 15. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, 2018-2027 (USD BILLION)
TABLE 16. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY STATE, 2018-2027 (USD BILLION)
TABLE 17. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, 2018-2027 (USD BILLION)
TABLE 18. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY STATE, 2018-2027 (USD BILLION)
TABLE 19. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, 2018-2027 (USD BILLION)
TABLE 20. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY STATE, 2018-2027 (USD BILLION)
TABLE 21. CALIFORNIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 22. CALIFORNIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 23. CALIFORNIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 24. FLORIDA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 25. FLORIDA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 26. FLORIDA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 27. ILLINOIS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 28. ILLINOIS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 29. ILLINOIS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 30. NEW YORK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 31. NEW YORK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 32. NEW YORK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 33. OHIO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 34. OHIO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 35. OHIO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 36. PENNSYLVANIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 37. PENNSYLVANIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 38. PENNSYLVANIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 39. TEXAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 40. TEXAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2027 (USD BILLION)
TABLE 41. TEXAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 42. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 43. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 44. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 45. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 46. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 47. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET MERGER & ACQUISITION
TABLE 48. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 49. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 50. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET INVESTMENT & FUNDING
TABLE 51. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 52. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings